Tema Neuroscience and Mental Health ETF (MNTL)
| Assets | $11.15M |
| Expense Ratio | 0.75% |
| PE Ratio | 24.37 |
| Shares Out | 440,000 |
| Dividend (ttm) | $0.26 |
| Dividend Yield | 1.02% |
| Ex-Dividend Date | Dec 11, 2024 |
| Payout Ratio | 24.83% |
| 1-Year Return | +1.48% |
| Volume | 212 |
| Open | 25.28 |
| Previous Close | 25.23 |
| Day's Range | 25.28 - 25.55 |
| 52-Week Low | 23.67 |
| 52-Week High | 27.66 |
| Beta | n/a |
| Holdings | 51 |
| Inception Date | Jan 22, 2024 |
About MNTL
Fund Home PageThe Tema Neuroscience and Mental Health ETF (MNTL) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, concentrating on companies engaged in addressing disorders of the central nervous system and mental health worldwide. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. MNTL was launched on Jan 22, 2024 and is issued by Tema.
Top 10 Holdings
47.27% of assets| Name | Symbol | Weight |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 9.26% |
| argenx SE | ARGX | 5.28% |
| Neurocrine Biosciences, Inc. | NBIX | 5.21% |
| Eli Lilly and Company | LLY | 5.16% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 4.91% |
| Teva Pharmaceutical Industries Limited | TEVA | 4.02% |
| Regeneron Pharmaceuticals, Inc. | REGN | 3.92% |
| Biogen Inc. | BIIB | 3.21% |
| Medtronic plc | MDT | 3.17% |
| Crinetics Pharmaceuticals, Inc. | CRNX | 3.13% |
News
Hone Your Biotech Allocation in Neuroscience ETF MNTL
Tech investing poses one of the more important, and more fascinating, questions before investors entering 2025. Tech firms contributed outsized returns for the whole market, but do they pose concentra...
MNTL ETF: Neuroscience & Mental Health ETF
Tema ETFs recently launched the neuroscience and mental health ETF. MNTL ETF is designed to invest in companies at the forefront of combating neurological diseases and psychiatric disorders.